Logo image of RNA

AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RNA - US05370A1088 - Common Stock

71.54 USD
-0.04 (-0.06%)
Last: 12/4/2025, 4:30:01 PM
71.54 USD
0 (0%)
After Hours: 12/4/2025, 4:30:01 PM
Fundamental Rating

4

Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 534 industry peers in the Biotechnology industry. RNA has a great financial health rating, but its profitability evaluates not so good. RNA shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RNA had negative earnings in the past year.
In the past year RNA has reported a negative cash flow from operations.
In the past 5 years RNA always reported negative net income.
RNA had a negative operating cash flow in each of the past 5 years.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of RNA (-25.76%) is better than 71.54% of its industry peers.
RNA has a Return On Equity of -29.15%. This is in the better half of the industry: RNA outperforms 78.09% of its industry peers.
Industry RankSector Rank
ROA -25.76%
ROE -29.15%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
Compared to 5 years ago, RNA has more shares outstanding
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RNA has an Altman-Z score of 25.29. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
RNA has a better Altman-Z score (25.29) than 91.95% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.29
ROIC/WACCN/A
WACC8.7%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

RNA has a Current Ratio of 11.57. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RNA (11.57) is better than 85.77% of its industry peers.
RNA has a Quick Ratio of 11.57. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
RNA's Quick ratio of 11.57 is amongst the best of the industry. RNA outperforms 85.77% of its industry peers.
Industry RankSector Rank
Current Ratio 11.57
Quick Ratio 11.57
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

RNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.14%.
Looking at the last year, RNA shows a very strong growth in Revenue. The Revenue has grown by 106.27%.
The Revenue has been growing by 36.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%

3.2 Future

The Earnings Per Share is expected to grow by 23.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 180.87% on average over the next years. This is a very strong growth
EPS Next Y-55.1%
EPS Next 2Y-30.58%
EPS Next 3Y-10.04%
EPS Next 5Y23.37%
Revenue Next Year7.76%
Revenue Next 2Y50.06%
Revenue Next 3Y227.85%
Revenue Next 5Y180.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as RNA's earnings are expected to decrease with -10.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.58%
EPS Next 3Y-10.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIDITY BIOSCIENCES INC

NASDAQ:RNA (12/4/2025, 4:30:01 PM)

After market: 71.54 0 (0%)

71.54

-0.04 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners100.03%
Inst Owner Change14.66%
Ins Owners0.83%
Ins Owner Change-0.14%
Market Cap10.78B
Revenue(TTM)20.87M
Net Income(TTM)-549.79M
Analysts73.68
Price Target73.37 (2.56%)
Short Float %7.26%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.79%
Min EPS beat(2)-21.39%
Max EPS beat(2)-14.2%
EPS beat(4)1
Avg EPS beat(4)-8.77%
Min EPS beat(4)-21.39%
Max EPS beat(4)0.55%
EPS beat(8)3
Avg EPS beat(8)-3.28%
EPS beat(12)7
Avg EPS beat(12)1.34%
EPS beat(16)9
Avg EPS beat(16)0.21%
Revenue beat(2)2
Avg Revenue beat(2)349.15%
Min Revenue beat(2)158.88%
Max Revenue beat(2)539.42%
Revenue beat(4)3
Avg Revenue beat(4)193.33%
Min Revenue beat(4)-18.03%
Max Revenue beat(4)539.42%
Revenue beat(8)4
Avg Revenue beat(8)82.38%
Revenue beat(12)8
Avg Revenue beat(12)61.99%
Revenue beat(16)10
Avg Revenue beat(16)45.62%
PT rev (1m)5.61%
PT rev (3m)6.89%
EPS NQ rev (1m)-2.88%
EPS NQ rev (3m)-0.85%
EPS NY rev (1m)0.15%
EPS NY rev (3m)1.26%
Revenue NQ rev (1m)51.84%
Revenue NQ rev (3m)40.15%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)3.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 516.56
P/FCF N/A
P/OCF N/A
P/B 5.71
P/tB 5.71
EV/EBITDA N/A
EPS(TTM)-4.18
EYN/A
EPS(NY)-4.93
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-3.85
OCFYN/A
SpS0.14
BVpS12.52
TBVpS12.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.76%
ROE -29.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 439.11%
Cap/Sales 71.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.57
Quick Ratio 11.57
Altman-Z 25.29
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
EPS Next Y-55.1%
EPS Next 2Y-30.58%
EPS Next 3Y-10.04%
EPS Next 5Y23.37%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%
Revenue Next Year7.76%
Revenue Next 2Y50.06%
Revenue Next 3Y227.85%
Revenue Next 5Y180.87%
EBIT growth 1Y-88.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.83%
EBIT Next 3Y-1.52%
EBIT Next 5YN/A
FCF growth 1Y-232.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-232.19%
OCF growth 3YN/A
OCF growth 5YN/A

AVIDITY BIOSCIENCES INC / RNA FAQ

Can you provide the ChartMill fundamental rating for AVIDITY BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 4 / 10 to RNA.


Can you provide the valuation status for AVIDITY BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to AVIDITY BIOSCIENCES INC (RNA). This can be considered as Overvalued.


Can you provide the profitability details for AVIDITY BIOSCIENCES INC?

AVIDITY BIOSCIENCES INC (RNA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AVIDITY BIOSCIENCES INC?

The Earnings per Share (EPS) of AVIDITY BIOSCIENCES INC (RNA) is expected to decline by -55.1% in the next year.